BACKGROUND: Single-nucleotide polymorphisms in the promoter region of the FAS and FASLG may alter the transcriptional activity of these genes. We therefore investigated the association between the FAS and FASLG polymorphisms and risk for second primary malignancy (SPM) after index squamous cell carcinoma of the head and neck (SCCHN). METHODS: We used log-rank test and Cox proportional hazard models to assess the association of the four single-nucleotide polymorphisms (FAS -1377 G > A, FAS -670 A > G, FASLG -844 C > T, and FASLG -124 A > G) with the SPM-free survival and SPM risk among 1,286 incident SCCHN patients. RESULTS: Compared with patients having the FAS -670 AA or the FASLG -844 CC genotypes, the patients having variant genotypes of FAS -670 AG/GG or FASLG -844 CT/TT genotypes had significantly increased risk for SPM, respectively. A trend for significantly increased SPM risk with increasing number of risk genotypes of the four polymorphisms was observed in a dose-response manner. Moreover, the patients with three or four combined risk genotypes had an approximately 1.8- or 2.5-fold increased risk for developing SPM compared with patients with zero or one risk genotypes, respectively. CONCLUSIONS: Our results suggest a modestly increased risk for SPM after index SCCHN with FAS -670 A > G and FASLG -844 C > T polymorphisms and an even greater risk for SPM with multiple combined FAS and FASLG risk genotypes. IMPACT: The FAS and FASLG polymorphisms may serve as a susceptible marker for SCCHN patients at high SPM risk. Copyright 2010 AACR.
BACKGROUND: Single-nucleotide polymorphisms in the promoter region of the FAS and FASLG may alter the transcriptional activity of these genes. We therefore investigated the association between the FAS and FASLG polymorphisms and risk for second primary malignancy (SPM) after index squamous cell carcinoma of the head and neck (SCCHN). METHODS: We used log-rank test and Cox proportional hazard models to assess the association of the four single-nucleotide polymorphisms (FAS -1377 G > A, FAS -670 A > G, FASLG -844 C > T, and FASLG -124 A > G) with the SPM-free survival and SPM risk among 1,286 incident SCCHN patients. RESULTS: Compared with patients having the FAS -670 AA or the FASLG -844 CC genotypes, the patients having variant genotypes of FAS -670 AG/GG or FASLG -844 CT/TT genotypes had significantly increased risk for SPM, respectively. A trend for significantly increased SPM risk with increasing number of risk genotypes of the four polymorphisms was observed in a dose-response manner. Moreover, the patients with three or four combined risk genotypes had an approximately 1.8- or 2.5-fold increased risk for developing SPM compared with patients with zero or one risk genotypes, respectively. CONCLUSIONS: Our results suggest a modestly increased risk for SPM after index SCCHN with FAS -670 A > G and FASLG -844 C > T polymorphisms and an even greater risk for SPM with multiple combined FAS and FASLG risk genotypes. IMPACT: The FAS and FASLG polymorphisms may serve as a susceptible marker for SCCHN patients at high SPM risk. Copyright 2010 AACR.
Authors: J Cloos; C R Leemans; M L van der Sterre; D J Kuik; G B Snow; B J Braakhuis Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-07 Impact factor: 4.254
Authors: Kim-Anh Do; Marcella M Johnson; Dorota A Doherty; J Jack Lee; Xi Feng Wu; Qiong Dong; Waun K Hong; Fadlo R Khuri; Karen K Fu; Margaret R Spitz Journal: Cancer Causes Control Date: 2003-03 Impact factor: 2.506
Authors: Jianming Wu; Christine Metz; Xiulong Xu; Riichiro Abe; Andrew W Gibson; Jeffrey C Edberg; Jennifer Cooke; Fenglong Xie; Glinda S Cooper; Robert P Kimberly Journal: J Immunol Date: 2003-01-01 Impact factor: 5.422
Authors: Mark E Zafereo; Erich M Sturgis; Zhensheng Liu; Li-E Wang; Qingyi Wei; Guojun Li Journal: Carcinogenesis Date: 2009-04-15 Impact factor: 4.944
Authors: Athanassios Argiris; Bruce E Brockstein; Daniel J Haraf; Kerstin M Stenson; Bharat B Mittal; Merrill S Kies; Fred R Rosen; Borko Jovanovic; Everett E Vokes Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Kathryn Sibley; Sara Rollinson; James M Allan; Alexandra G Smith; Graham R Law; Philippa L Roddam; Christine F Skibola; Martyn T Smith; Gareth J Morgan Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Fenghua Zhang; Erich M Sturgis; Yan Sun; Yang Zhang; Qingyi Wei; Caiyun Zhang; Hongliang Zheng; Guojun Li Journal: Int J Cancer Date: 2015-07-27 Impact factor: 7.396
Authors: Dafeng Yang; Christina M Torres; Kankana Bardhan; Mary Zimmerman; Tracy L McGaha; Kebin Liu Journal: J Immunol Date: 2012-03-28 Impact factor: 5.422